AUTHORS
Zhuoer Xie, MD,MS, J. Scott Austin Beeler, MD, PhD2, Tarun Bhagnani, MS, BPharm3, Weilong Li4, Anne Angiolillo, MD5, Prapti Patel6, Eros Papademetriou7, Debasish Mazumder8, Rami Komrokji, MD9, Kelly Bolton, MD, PhD10
AFFILIATIONS
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Washington University in St. Louis, St. Louis, Missouri, United States
3 Servier Pharmaceuticals, Boston, Massachusetts, United States
4 Servier Pharmaceuticals, Boston, Massachusetts, United States
5 Servier Pharmaceuticals, Boston, Massachusetts, United States
6 Servier Pharmaceuticals, Boston, Massachusetts, United States
7 Inizio Ignite Putnam, New York, New York, United States
8 Inizio Ignite Putnam, Gurgaon, India
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Washington University in St. Louis, St. Louis, Missouri, United States
ABSTRACT
Background: Ivosidenib (IVO) monotherapy (mono) was approved in the US for adults with relapsed or refractory (R/R) mutant isocitrate dehydrogenase 1 (mIDH1) myelodysplastic syndromes (MDS). In the Phase 1 registrational trial supporting this indication, the median treatment duration was 9.3 months, and median overall survival (OS) was 35.7 months over a median follow-up period of 27.1 months. However, although IVO is increasingly used in the frontline (1L) setting in clinical practice, real-world evidence describing the effectiveness across different lines of therapy remains limited. This study describes treatment patterns and clinical outcomes among patients with mIDH1 MDS who were treated with IVO in both the 1L and relapsed/refractory settings.
Methods: This retrospective cohort study used closed medical and pharmacy claims from the Komodo Research Dataset (January 1, 2016 to May 30, 2026). Patients were included if they had a confirmed MDS diagnosis (identified using ICD-10 codes: D46.0, D46.1, D46.2, D46.A, D46.B, and D46.9), initiated IVO on or after July 1, 2018, were ≥18 years at diagnosis, had ≥180 days of medical and pharmacy coverage before diagnosis, and had no other hematologic malignancy or MDS treatment 180 days prior to MDS diagnosis. Patients were excluded if they initiated IVO after transformation into acute myeloid leukemia. Baseline characteristics and outcomes for IVO-treated patients were described by lines of therapy (1L or later lines [2L+]) and mono or combination therapy (combo). Outcomes included duration of treatment (DoT), OS (defined as time from the start of first IVO use to earliest of death, continuous enrollment or the end of follow-up), transfusion independence (defined as an observed 8-week gap between 2 consecutive transfusion procedures from the start to end of IVO treatment), and stem cell transplantation (SCT). Descriptive statistics were used to assess baseline characteristics, and proportions of patients achieving transfusion independence, or receiving SCT. Kaplan–Meier methods were used to estimate DoT and OS.
Results: The study included 105 patients with MDS treated with IVO, of whom 48 initiated IVO in 1L and 57 in 2L+. Forty-nine received IVO mono (1L: 28; 2L+: 21) and 56 received IVO combo (1L: 20; 2L+: 36). Median age was 76 years, 56.2% were male, and median Charlson Comorbidity Index was 1. Median follow-up after IVO initiation was 10 months (11 months for 1L; 8 months for 2L+).
Median DoT was 14.8 months in 1L (mono: 20.4 months; combo: 14.8 months), and 5.3 months in 2L+ (mono: 12.3; combo: 4.5 months). Median OS was not reached (NR) in 1L (mono: NR; combo: 35.3 months). For the overall 2L+ cohort, median OS was 19.4 months (95% confidence interval: 8.8, not estimable; mono: NR; combo: 18.3 months).
Transfusion outcomes demonstrated clinical benefit with IVO across treatment settings. Among 45 patients who were transfusion dependent before IVO initiation, 17 (37.8%) achieved transfusion independence, including 5/8 (62.5%) in 1L and 12/37 (32.4%) in 2L+. Nine patients (8.6%) underwent SCT following IVO initiation (3 [6.3%] in 1L; 6 [10.5%] in 2L+).
Conclusions: This study provides the first real-world evaluation of IVO in patients with mIDH1 MDS. Outcomes observed with IVO mono in 2L+ settings were generally consistent with those reported in the Phase 1 registrational study, supporting the effectiveness of IVO in routine clinical practice for the approved R/R indication. The most favorable outcomes were observed with 1L IVO mono, including durable treatment, prolonged survival, and reduced transfusion burden. The use of IVO mono in the 1L setting is being further evaluated in the PyramIDH trial (NCT06465953). Favorable outcomes observed with mono provide additional real-world evidence to inform treatment decisions in this rare molecular subtype of MDS.
DISCLOSURES
Zhuoer Xie, MD,MS: No relevant conflicts of interest to declare.